News Releases:  Research

  • August 26, 2016 | $3,023,456 Five-Year Award Announced by NEI for Emory Eye Center Vision Research. (ATLANTA) Emory Eye Center Director of Research P. Michael Iuvone, PhD,  and his colleagues announced today the news of a first-year funding award of $624,000 for their “P30 Core Grant for Vision Research” proposal by the National Eye Institute (NEI), a division of the National Institutes of Health (NIH).

  • May 26, 2016 | Emory Eye Center Postdocs Honored at Emory Research Symposium
    (ATLANTA) Emory Eye Center’s postdoctoral research scientists placed among the top honorees at the May 19, 2016, Emory University School of Medicine 9th Annual Postdoctoral Research Symposium.  This symposium featured work from more than 100 postdoctoral fellows from the Emory campus.

  • May 25, 2016 | Top Southeastern U.S. Vision Research Scientists Gather for Symposium on Retinal Degeneration. (ATLANTA) On May 18, Emory Eye Center co-hosted, with the Atlanta VAMC Center for Visual & Neurocognitive Rehabilitation (CVNR), the “AVRC Retinal Degeneration Symposium” on the Emory University campus.

  • May 16, 2016 | Researchers Honored at 2016 ARVO Annual Meeting. (ATLANTA) With 60 scientific papers, posters and symposiums, Emory Eye Center researchers were leading scientific contributors to the Association for Research in Vision and Ophthalmology (ARVO) 2016 Annual Meeting, “Research: A Vision for Hope,” in Seattle, Washington, May 1-5. Their topics ranged from groundbreaking research on ocular melanoma to challenges and discoveries on Ebola and the eye.

  • December 17, 2015 | Emory Eye Center receives gift for glaucoma research from Douglas County resident Lewis. (ATLANTA) Douglas County resident Jim Lewis, former attorney and judge, has recently helped fund medical research in three departments at Emory University’s School of Medicine. Those departments include ophthalmology (Emory Eye Center); cancer (Winship Cancer Institute); and Alzheimer’s disease (Alzheimer’s Disease Research Center). Lewis donated $100,000 to each of the entities with the cancer research funding to be divided equally between colon and lung cancers.

  • December 16, 2015 | Entolimod Shown to Suppress Liver Metastases in Model of Ocular Melanoma in Collaborative Study by Cleveland BioLabs, Emory University and Roswell Park Cancer Institute. Buffalo, NY, Cleveland BioLabs, Inc. (NASDAQ:CBLI), Emory University and Roswell Park Cancer Institute (RPCI) today announced the publication of a study in Oncotarget demonstrating the ability of entolimod to suppress liver metastases in a preclinical model of uveal melanoma (UM). The study was led by Hans Grossniklaus MD, Professor of Ophthalmology, Director of the L.F. Montgomery Pathology Laboratory and Director of the Section of Ocular Oncology and Pathology at Emory Eye Center, Emory University, and Lyudmila Burdelya, PhD, Assistant Professor of Oncology in the Department of Cell Stress Biology at RPCI.

  • December 3, 2015 | Emory Eye Center mourns loss of Professor Emeritus Henry F. Edelhauser. Emory Eye Center is sad to announce the passing of Henry F. Edelhauser, former director of research for Emory Eye Center (1989-2013).

  • August 29, 2015 | Emory Eye Center to host Southeastern Ocular Oncology/Pathology Seminar Friday, Sept. 25. The seminar is designed for primary care physicians, ophthalmologists and oncologists interested in increasing knowledge in identifying and treating ocular malignancies and applying this knowledge in clinical practice.

  • April 7, 2015 | Emory Eye Center’s Bruce awarded a 2014 Clinical Care Innovation Challenge Award by AAMC . (Atlanta) Emory Eye Center neuro-ophthalmologist Beau Bruce, MD, PhD, has been tapped as a 2014 Association of American Medical Colleges (AAMC) Clinical Care Challenge Award winner for his work on non-mydriatic ocular fundus photography in the emergency department.

  • April 28, 2014 | Emory Eye Center and NEI release findings of trial for those with idiopathic intracranial hypertension (IIH)
    For patients with idiopathic intracranial hypertension (IIH), national study findings released this week show that an inexpensive drug, acetazolamide, improves vision for patients who have mild visual loss when combined with a weight loss plan.

  • March 7, 2014 | Emory Eye Center lead center in five-year study on infants vision after cataract surgery: Results say contact lenses better long term than implanted lenses. (ATLANTA) A five-year nationwide study based at Emory Eye Center has reported new findings for babies who have undergone cataract surgery. The clinical trial suggests that for most infants who have had cataract surgery, the use of contact lenses for several years—and an eventual lens implant—may be the better solution than the standard of care, the intraocular lens implant following surgery.

  • Feb. 12, 2014 | Exercise may slow retinal degeneration . Moderate aerobic exercise helps to preserve the structure and function of nerve cells in the retina after damage, researchers at the Emory Eye Center and the Atlanta VA Medical Center have found. The findings, from a study of an animal model of age-related macular degeneration, are the first to suggest that aerobic exercise can have a direct effect on retinal health and vision.

  • Jan. 21, 2014 | Parkinson's drugs could provide new avenue to treat diabetes-related vision problems .
    Dopamine-restoring drugs already used to treat Parkinson's disease may also be beneficial for the treatment of diabetic retinopathy, a leading cause of blindness in adults, researchers have discovered. The results were published recently in Journal of Neuroscience.

  • Emory Eye Center researcher's book demonstrates relationship between the retina and circadian rhythms
    Jan. 15, 2014 | (Atlanta) Emory Eye Center Director of Research, P. Michael Iuvone, the Sylvia Montag Ferst and Frank W. Ferst Professor of Ophthalmology, has published a new book, The Retina and Circadian Rhythms (Springer, 2014), along with fellow editors Gianluca Tosini (Morehouse College of Medicine), Douglas G. McMahon (Vanderbilt University), and Shaun P. Collin (University of Western Australia).

  • Emory Eye Center a site for Childhood Glaucoma Research Network's international research project : First-of-its-kind survey seeks significant advancement by investigating worldwide treatment outcomes for childhood glaucoma.
    May 30, 2013 | (Atlanta) Emory Eye Center will join 15 other eye centers throughout the world participating in the Childhood Glaucoma Research Network's (CGRN) newly launched International Pilot Survey of Childhood Glaucoma (IPSOCG), its first collaborative international clinical research project.

  • NEI study conducted at Emory provides clarity on supplements for protection against AMD
    May 9, 2013 | (ATLANTA) Emory Eye Center clinical research contributed to the recent findings of a multi-year National Eye Institute (NEI) study, AREDS2 (Age-Related Eye Disease Study). Results concluded that adding omega-3 fatty acids did not improve a combination of nutritional supplements commonly recommended for treating age-related macular degeneration (AMD), a major cause of vision loss among older Americans.

  • Emory Eye Center Recipient of Knights Templar Award
    February 27, 2013 | (ATLANTA) The Emory Eye Center was recently awarded $32,000 by the Georgia Knights Templar Educational Foundation, Inc. The funding will be used to continue important educational and research opportunities that impact the entire state of Georgia. Over the past several years, the Georgia Knights Templar has awarded $750,000 to the Emory Eye Center.

  • Emory Eye Center's Nickerson receives top ARVO award
    Feb. 19, 2013 | (ATLANTA) The Association for Research in Vision and Ophthalmology (ARVO) has announced this year's class of distinguished Fellows. Eye Center faculty member and researcher John M. Nickerson, PhD, has been awarded the prestigious Gold Fellow status by ARVO, the premier vision research organization in the world.

  • Emory Eye Center Faculty Receive Top ARVO Awards
    Feb. 9, 2012 | (ATLANTA) The Association for Research in Vision and Ophthalmology (ARVO) has announced this year's class of distinguished Fellows. Two Eye Center faculty members have been awarded the prestigious Gold Fellow status. Additionally, Henry F. Edelhauser, PhD, former director of research, will be honored at the ARVO Foundation for Eye Research (AFER) Gala Dinner for his lifetime of work in eye research. All three awards will take place during the spring national meeting in Florida.

  • Startup Receives $4 Million to Develop Drug Delivery Targeted to the Back of the Eye
    Jan. 5, 2012 | (ATLANTA) Technology developed by researchers at the Georgia Institute of Technology and Emory University for delivering drugs and other therapeutics to specific locations in the eye provides the foundation for a startup company that has received a $4 million venture capital investment.

  • Newly Patented Microneedle for Ocular Drug Delivery: Smaller is Better
    April 28, 2011 | (ATLANTA) A goal of ophthalmology researchers is to deliver medication to the back of the eye in a selective and minimally invasive way. An Emory Eye Center scientist and two fellow researchers have investigated opportunities and have recently been awarded a U.S. patent for application of microneedle technology, designed to do just that. Filed for in 2007 and awarded in April 2011, the patent (US 7,918,814) was awarded to Henry F. Edelhauser, Emory Eye Center’s former director of research, along with Mark Prausnitz, professor of chemical and biomedical engineering at the Georgia Institute of Technology, and Ninghao Jiang, a research graduate student at Georgia Tech, now employed at CNA, a non-profit research organization in Virginia.

  • NIH Study Finds Avastin and Lucentis Are Equally Effective In Treating Age-Related Macular Degeneration
    April 29, 2011 | (ATLANTA) Emory Eye Center and other study centers have been a part of a two-year national clinical trial evaluating two drugs for age-related macular degeneration (AMD). Results from the first year of the trial among 43 eye institutions show that Avastin—a drug approved to treat some cancers and that is commonly used off-label to treat age-related macular degeneration (AMD)—is as effective as the Food and Drug Administration-approved drug Lucentis for the treatment of AMD.

  • Emory Eye Center Researcher Elected President of National Research Organization

    July 9, 2010 | (ATLANTA) Emory Eye Center Associate Professor Jeffrey Boatright, PhD, has been voted president of the Association for Research in Vision and Ophthalmology (ARVO). ARVO is the premier vision research organization in the United States. He will assume the presidency in May 2011. Founded in 1928 in Washington, D.C., by 73 ophthalmologists, the Association's membership now numbers more than 12,500 individuals and continues to grow. Some 42% of members reside in over 80 countries outside the United States. The membership is multidisciplinary and consists of both clinical and basic researchers. ARVO encourages and assists research, training, publication and knowledge-sharing in vision and ophthalmology.

  • Emory Eye Center Receives RPB Funding for Continued Research
    June 25, 2010 | (ATLANTA) Emory Eye Center has received a one-year departmental grant for $100,000 from Research to Prevent Blindness (RPB). The grant will help support research into the causes, treatment and prevention of blinding diseases. The research will be directed by Timothy W. Olsen, director, Emory Eye Center and chair, Department of Ophthalmology within Emory University’s School of Medicine.

  • Emory Eye Center Researcher Edelhauser to Present Charles D. Kelman Innovator’s Lecture at American Society of Cataract and Refractive Surgeons
    April 2, 2010 | (ATLANTA) Emory Eye Center research professor Henry F. Edelhauser, PhD, has been named the Charles D. Kelman Innovator’s Lecturer for the national meeting of the American Society of Cataract and Refractive Surgeons (ASCRS) meeting in April. The ASCRS lectureship honors the work of individuals whose creativity has benefited ophthalmologists and their patients. The lecture is presented during a special session at the annual ASCRS Symposium on Cataract, IOL and Refractive Surgery. Charles D. Kelman, MD, presented the first lecture in 1985. In recognition of the ongoing contribution of the late Dr. Kelman to anterior segment surgery—the invention of phacoemulsification—the lecture was renamed for him in 2003. Dr. Edelhauser’s title is “Evolution of Surgical Pharmacology: Reviewing the Past and Looking to the Future.”

  • Researcher Awarded Senior Scientific Investigator Award
    January 14, 2010 | (ATLANTA) P. Michael Iuvone, PhD, director of research at Emory Eye Center, has been granted a $75,000 Senior Scientific Investigator Award by Research to Prevent Blindness (RPB). The award supports nationally recognized senior scientists conducting eye research at medical institutions in the United States. Dr. Iuvone was one of 169 scientists at 56 institutions so honored since the award was established in 1987.

  • Emory Eye Center Research Director Michael Iuvone Appointed to Sylvia Montag Ferst and Frank W. Ferst Endowed Research Chair
    (ATLANTA) P. Michael Iuvone, PhD, who recently joined Emory Eye Center as director of research, has been appointed to the Sylvia Montag Ferst and Frank W. Ferst Endowed Research Chair. The chair was created in 1988 through a generous $3 million gift from Sylvia and Frank Ferst for the purpose of supporting research in ophthalmology.

  • Emory Eye Center Starts Study for Infants with Blocked Tear Ducts
    (ATLANTA) Emory Eye Center will participate in third phase of a National Eye Institute (NEI)-sponsored multicenter clinical trial, the Nasolacrimal Duct Obstruction (NLDO) Study in late winter. The trial will evaluate which of two approaches is optimal in treating young infants with blocked tear duct: probing the obstruction immediately or waiting to see if the condition goes away on its own after six months, as is often the case.

  • Michael Iuvone Joins Emory Eye Center as Director of Research
    May 8, 2009 | (ATLANTA) P. Michael Iuvone, PhD, professor, Department of Pharmacology, Emory University School of Medicine, will serve as director of research at Emory Eye Center, effective Sept. 1, 2009. Iuvone will take the lead role in vision research at the Emory Eye Center and continue the national reputation of scientific excellence that Henry F. Edelhauser, MD, has cultivated over the past two decades.

  • Three Emory Eye Center Scientists Named ARVO 2009 Fellows
    May 1, 2009 | (ATLANTA) The Association for Research in Vision and Ophthalmology (ARVO) has announced this year’s inaugural class of distinguished Fellows. Three Eye Center scientists will be honored at this year’s annual meeting in early May: Henry F. Edelhauser, PhD, was awarded the highest distinction, Gold Fellow; Hans E. Grossniklaus, MD, MBA, and John M. Nickerson, PhD, were each awarded Silver Fellow distinctions.

  • Clinical Trial Aims to Help Those with Macular Degeneration Find New Way of Seeing

    emptyDecember 4, 2008 | (ATLANTA) The brain’s remarkable ability to reorganize itself to compensate for vision loss, the ability called plasticity, may be the key in helping those with age-related macular degeneration (AMD) see better. This theory is the impetus behind a study between Emory Eye Center and the Georgia Institute of Technology (Psychology). Patients who have retinal damage because of AMD sometimes begin to see by using other parts of the intact retina.

  • Emory Eye Center Awarded Grant from Research to Prevent Blindness
    (ATLANTA) Research to Prevent Blindness (RPB) has given Emory Eye Center a $110,000 unrestricted grant to fund research. RPB is the world’s leading voluntary organization supporting eye research. To date, RPB has awarded grants totaling $3,112,100 to Emory University School of Medicine for eye research. RPB’s research at Emory Eye Center will be directed by Timothy W. Olsen, director, Emory Eye Center and chair, Department of Ophthalmology.
    Aug. 14, 2008

  • Emory Eye Center Participates in Nationwide Study Showing that Older Corneas are Suitable for Transplantation Results Could Expand Donor Pool Significantly
    ATLANTA- Corneal transplants using tissue from older donors have similar rates of survival to those using tissue from younger donors reports a nationwide study recently concluded at Emory Eye Center and 79 other sites. The five-year transplant success rate for recipients was the same—86 percent—for transplants performed across the nation with corneas from donors ages 12 to 65 years and from donors ages 66 to 75.
    April 1, 2008

  • Study Alerts Eye Doctors of Racial Differences in Treating Vision Disorders
    (ATLANTA) Blacks are more likely to lose vision due to increased pressure in the brain than other races, reports an Emory Eye Center researcher in the March 11, 2008 issue of Neurology, the journal of the American Academy of Neurology. The pressure, called idiopathic intracranial hypertension, was identified as causing the disorder, says Beau Bruce, MD, MS, a neuro-ophthalmology fellow at the Emory University School of Medicine and lead researcher for the study.
    March 12, 2008

  • Emory Eye Center to Lead Nationwide Study to Compare Two Drugs That Treat Macular Degeneration
    (ATLANTA) Emory Eye Center will be the lead center among 47 other eye institutions across the country in a National Eye Institute (NEI) / National Institutes of Health funded study to compare two drugs made by the same company that treat age-related macular degeneration (AMD).
    March 4, 2008

  • Emory Eye Center Awarded Grant from Foundation Fighting Blindness for Retinal Degeneration
    ATLANTA - Emory Eye Center recently was awarded a $309,000 grant for three years from the Foundation Fighting Blindness (FFB) to support the study of synthetic bile acids to treat retinal degeneration.
    Aug. 6, 2007 

  • Emory Eye Center Awarded Grant from Research to Prevent Blindness
    (ATLANTA) The Emory Eye Center is the recipient of a $110,000 unrestricted grant to fund research from the Research to Prevent Blindness (RPB), the world’s leading voluntary organization supporting eye research.
    July 16, 2007

  • Emory Eye Center Researcher Tapped as Trustee to Prestigious Research Organization
    ( ATLANTA) At the recent meeting of the Association for Research in Vision and Ophthalmology (ARVO) held May 6-10 in Ft. Lauderdale, Fla., Emory Eye Center researcher Jeffrey H. Boatright, PhD, was elected as trustee for the Biochemistry and Molecular Biology Section. During his five-year term he will serve along with 13 other trustees who manage the affairs of ARVO. Trustees are elected from candidates put forth by the Association’s 13 Scientific Sections. The Association is the premier professional society in Dr. Boatright’s field.
    May 23, 2007

  • Emory Ophthalmology Researcher Collaborates for Guidelines for Optimal Surgical Outcomes
    (ATLANTA) In a move to provide guidelines for better ophthalmic surgical outcomes, Emory Eye Center’s Henry F. Edelhauser, PhD, director of research, along with a selected committee of professionals— the Ad Hoc Task Force on Cleaning and Sterilization of Intraocular Instruments— came together last fall at Emory University to tackle the difficult issue of ophthalmic instrument cleaning and sterilization.
    April 5, 2007

  • Emory Eye Center Physician Awarded Senior Scientific Investigator Award by RPB
    (ATLANTA) Emory Eye Center’s Hans. E. Grossniklaus, MD, MBA, the F. Phinizy Calhoun Jr. Professor of Ophthalmology and Director of the L.F. Montgomery Pathology Laboratory, has been granted a $75,000 Senior Scientific Investigator Award by Research to Prevent Blindness (RPB). RPB Senior Scientific Investigator Awards support nationally recognized senior scientists conducting eye research at medical institutions in the United States. Dr. Grossniklaus, an ophthalmologist and ocular pathologist, is one of 147 scientists at 55 institutions so honored since the award was established in 1987.
    Jan. 18, 2007

  • Traditional Chinese Medicine Component May Yield Help In Retinal Degenerations Say Emory Eye Center Researchers
    ATLANTA - We may live in the 21st century, but it appears that the traditional or ancient medicines of Asia may be key preventing the ravaging effects of retinal degenerations that can ultimately cause blindness.
    January 8, 2007

  • Emory Eye Center Study Finds Laser Treatment Does Not Prevent Vision Loss for People with Early Age-Related Macular Degeneration
    (ATLANTA) Low-intensity laser treatment, thought to be possibly beneficial in slowing or preventing the loss of vision from age-related macular degeneration (AMD), is ineffective in preventing complications of AMD or loss of vision, according to a study published in the November 2006 journal Ophthalmology.
    November 2, 2006

  • New Nationwide Study Will Evaluate Effect of Antioxidants and Fish Oil on Progression of Age-Related Macular Degeneration (AMD): Nearly 100 Clinical Centers Are Now Seeking 4,000 Study Participants
    Ages 50 - 85 Who Have AMD
    (ATLANTA) Emory Eye Center along with other eye centers across the country will be a part of The National Institutes of Health (NIH) nationwide study to see if a modified combination of vitamins, minerals, and fish oil can further slow the progression of vision loss from AMD, the leading cause of vision loss in the United States for people over age 60.
    October 12, 2006

  • Macular Degeneration Immune Studies at Emory Eye Center Receive $1 Million Grant From Dobbs FoundationNew Researcher Santa Jeremy Ono Will Establish Dobbs Laboratory for AMD
    ATLANTA- Emory Eye Center has been awarded a a $1 million grant from the R. Howard Dobbs, Jr. Foundation. The grant will support the research of Santa Jeremy Ono, PhD, by establishing a new laboratory to investigate the role of immunity in the pathogenesis of age-related macular degeneration (the leading cause of blindness in aged individuals).
    September 21, 2006

  • Research at Emory Eye Center Contributes to FDA Approval of New Treatment For Wet Age-Related Macular Degeneration
    (ATLANTA) Emory Eye Center retina specialists participated in clinical trials that have concluded that a new drug holds hope in the treatment of age-related macular degeneration (AMD). Clinical trials here at Emory and throughout the country have lead to U.S. Food and Drug Administration (FDA) approval of Lucentis™ (ranbizumab injection), a new intravitreal drug that treats the “wet” type of macular degeneration. The drug is made by Genentech.
    July 25, 2006

  • Emory Eye Center Researchers Awarded NEI R24 Grant to Study Drug Delivery to the Eye
    ATLANTA - Emory Eye Center's Director of Research Henry F. Edelhauser, PhD, along with a team of co-principal investigators from the Eye Center and three other institutions have been awarded an R-24 grant by the National Eye Institute (NEI) for five years. The direct annual costs will run approximately $1.2 million per year. The grant is only the third R-24 grant awarded by the NEI. The collaboration was formed to improve drug delivery to the posterior segment of the eye. Drug delivery to this target is a significant challenge in the treatment of retinal disorders.
    June 15, 2006

  • Emory Eye Center Research Director Receives Proctor Award at Recent Association for Research in Vision & Ophthalmology (ARVO) Conference
    (ATLANTA) Henry F. Edelhauser, PhD, received the Proctor Medal and delivered the Proctor Lecture at the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO) in Ft. Lauderdale, Fla., on May 2. Dr. Edelhauser, the director of research for Emory Eye Center, was presented with ARVO's highest honor for his ground breaking work on the physiology of the corneal endothelium and for "elegant translational research from basic science to clinical applications."
    May 31, 2005

  • Emory Eye Center NEI study finds reduced daily eye patching effectively treats childhood's most common eye disorder
    A study conducted at Emory Eye Center and 35 other clinical sites found that patching the unaffected eye of children with moderate amblyopia for two hours daily works as well as patching the eye for six hours. This research finding should lead to better compliance with treatment and improved quality of life for children with amblyopia, or “lazy eye,” the most common cause of visual impairment in childhood.
    May 12, 2003

  • Emory Eye Center researchers identify lymphocytes required for Ocular Tolerance
    (ATLANTA) Unlike other parts of the body, the eye will tolerate the presence of foreign tissue in certain areas, such as the anterior chamber between the iris and the cornea, or the space underneath the retina. The same tissue placed elsewhere in the body, on the skin for example, would trigger an immune reaction and be rejected. Researchers at the Emory University School of Medicine in Atlanta, Ga., have studied this unique ability of the eye to develop methods to inhibit rejection by selectively enhancing immunological unresponsiveness, or “tolerance.” Yijun Xu, PhD and Judith A. Kapp, PhD, of the departments of Ophthalmology, Pathology and Winship Cancer Center, reported the results of their work in the November issue of Investigative Ophthalmology and Visual Science.
    Oct. 25, 2002

  • Emory Eye Center finds eye drops to treat childhood disorder can work as well as patching the eye
    (ATLANTA) A National Eye Institute (NEI) study, conducted at more than 40 sites nationwide including Emory Eye Center, has found that atropine drops, given once a day to treat amblyopia or lazy eye -- the most common cause of visual impairment in children -- work as well as the standard treatment of patching one eye. This research finding in the Amblyopia Treatment Study may lead to better compliance with treatment and improved quality of life in children with this eye disorder. These results appear in the March issue of Archives of Ophthalmology.
    March 11, 2002

  • Emory Eye Center Reports Important Findings from National AREDS Study: Macular Degeneration: Progression Can Be Slowed for Those at High Risk
    Findings were released today detailing the results of an important 10-year study which had a two-fold purpose:
    • To assess the clinical course, prognosis, and risk factors of age-related macular degeneration (AMD) and cataract.
    • To evaluate, in randomized clinical trials, the effects of pharmacologic doses of antioxidants and zinc on the progression of AMD and (2) antioxidants on the development and progression of lens opacities (cataract).
    Titled the Age- Related Eye Disease Study (AREDS), the clinical trial was conducted at 11 centers across the country, including the Emory Eye Center. The results show that there is a relatively simple way to help prevent the progression of age-related macular degeneration (AMD) in patients at high risk of the disease. “This is a particularly important finding since prior to this study, there was no way to slow the progression of AMD,” says Principal Investigator Daniel F. Martin, M.D., a vitreoretinal specialist at the Emory Eye Center. The AREDS was sponsored by the National Eye Institute (NEI), one of the federal government's National Institutes of Health. The study’s findings are reported in the October issue of Archives of Ophthalmology.
    Oct. 12, 2001

  • Emory Eye Center researcher finds similar survival rates for eye cancer therapies
    The National Eye Institute (NEI) has issued important research results stating that survival rates for two alternative treatments for primary eye cancer—radiation therapy and removal of the eye—are about the same. Emory Eye Center’s Paul Sternberg, Jr., M.D., was a primary investigator in the nationwide study, with results announced July 12. The clinical trial—called the Collaborative Ocular Melanoma Study (COMS)––was conducted at 43 institutions, including medical schools, hospitals, and doctors' offices, throughout the United States and Canada. The COMS trial was supported by the NEI and the National Cancer Institute (NCI), components of the National Institutes of Health (NIH). Prior to these findings, it was not known which treatment could result in lower mortality rates. Additionally, as a result of the study, the capability of doctors to provide more accurate diagnoses and state-of-the-art treatments for eye cancer has been greatly expanded, the findings report. Mortality data from the two treatments are compared in the July 2001 issue of Archives of Ophthalmology.
    July 31, 2001

  • Emory Eye Center receives core grant providing 20 consecutive years of funding
    Henry Edelhauser, Ph.D., director of research at the Emory Eye Center, and his colleagues have received $1.5 million in research dollars through the National Eye Institute (NEI), a division of the National Institutes of Health (NIH). The grant covers a five-year period, beginning in April. The NEI Core Center Grant includes three modules: 1) Structural Biology; 2) Analytical Biochemistry/Molecular Biology; and 3) Epidemiology and Biostatistics. Emory Eye Center's past Core Center Grant has successfully supported collaborative vision research and service, involving some 33 faculty (including more than 20 NEI-funded principal investigators), 20 postdoctoral fellows, six pre-doctoral fellows and generated more than 250 publications over the past five years.
    March 19, 2001

  • Emory researcher reveals effect of Lasik Surgery on Cornea three years following the procedure
    Emory Eye Center researcher Henry Edelhauser, Ph.D. and co-workers have completed a three-year study on Emory University Eye Center patients who underwent a laser in situ keratomileusis (LASIK) procedure, a refractive surgery to correct eyesight. The patients were evaluated to ascertain the long-term effects of such surgery on the corneal endothelium, the cells that line the inside of the cornea. Sometimes referred to as the "window to the world," the cornea is the transparent covering over the eye.
    March 13, 2001

  • Emory Medical School student awarded RPB funding to take a year off and do research at Emory Eye Center
    Not many medical students take a year off to enrich their education with research, but that's just what Emory University third-year medical student Chirag Parikh did in order to work with Emory Eye Center researcher Henry Edelhauser, Ph.D. Under the guidance of Dr. Edelhauser, whose expertise is corneal research, Parikh has found a second home, at least for this year.
    February 1, 2001

Our Emory campus location:

Copyright © Emory Eye Center - All Rights Reserved | Emory Clinic Building B, 1365B Clifton Road, NE, Atlanta, Georgia 30322 USA